Reference-product erosion, Purple Book status, interchangeability, payer switching, and specialty-channel uptake.
Six FDA-approved biosimilars now compete with Eylea (aflibercept) in ophthalmology, two with interchangeable designation. This reference-product dossier maps every...
Six FDA-approved biosimilars now compete with Herceptin (trastuzumab) in oncology. This reference-product dossier maps every approved product, payer formulary...
Ten FDA-approved biosimilars now compete with Humira (adalimumab). This reference-product dossier maps every approved product, interchangeability status, payer adoption,...
Interchangeability is a real FDA designation, but it is not a commercial launch plan. Here is what the Purple Book status does, what state substitution controls, and...